Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis ...
Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes ...
Chronická myelocytová leukémia – novinky z výročnej konferencie ASH® 2019
11 septembra, 2020 7:51 pmŠesťdesiata prvá výročná konferencia Americkej hematologickej spoločnosti (posledná v tomto desaťročí) – v skratke ASH® 2019 – sa konala od 7. do 10. 12....
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 704. Immunotherapies II Hematology Disease Topics & Pathways: Diseases,...
Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies:...
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell...
NOVINKY Z ASH® – AGRESÍVNE LYMFÓMY
11 septembra, 2020 7:51 pmV plenárnej sekcii boli prezentované výsledky štúdie fázy 1/1b GO2971, skúmajúcej bezpečnosť a účinnosť mosunetuzumabu v liečbe pacientov s relabovaným alebo refraktérnym difúznym veľkobunkovým...
Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study
11 septembra, 2020 7:51 pmProgram Oral and Poster Abstracts Session 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II Hematology Disease Topics...
Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II ...
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: First Line Treatment Hematology...